2 results
Approved WMOPending
To investigate the reliability and feasibility of PK-guided prophylactic dosing of factor concentrates in hemophilia A and B patients (predictive performance).
Approved WMOPending
Primary• To determine the efficacy of pelabresib + ruxolitinib compared with placebo + ruxolitinibKey Secondary• To determine the efficacy of pelabresib + ruxolitinib compared with placebo + ruxolitinibSecondary• To determine the effect of…